ProKidney Corp. (PROK)
After hours:
| Previous Close | 2.6100 |
| Open | 2.6500 |
| Bid | 2.8100 x 200 |
| Ask | 2.8700 x 200 |
| Day's Range | 2.6000 - 2.8500 |
| 52 Week Range | 1.1200 - 13.5100 |
| Volume | |
| Avg. Volume | 742,960 |
| Market Cap | 1.812B |
| Beta (5Y Monthly) | 1.11 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.5700 |
| Earnings Date | Aug 08, 2024 - Aug 12, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.00 |
- GuruFocus.com
ProKidney Corp Reports First Quarter 2024 Financial Results
Performance Analysis and Future Outlook Amidst Ongoing Clinical Developments
GlobeNewswireProKidney Reports Business Updates and First Quarter 2024 Financial Results
Final results from RMCL-002 Phase 2 trial to be presented in the Late Breaking Clinical Trials session at the European Renal Association (ERA) Congress on May 25, 2024. An investor call to provide a perspective on CKD with Dr. Arnold Silva and Dr. Steven Coca and a recap of the RMCL-002 data is planned for May 28, 2024On schedule to resume manufacturing and PROACT 1 Phase 3 trial, commence PROACT 2 Phase 3 trial, and readout interim results from the ongoing REGEN-007 Phase 2 trial in mid-2024Str
- GlobeNewswire
ProKidney Announces Key Leadership Appointments Strengthening Clinical and Technical Operations
Dr. Ulrich Ernst joins as Executive Vice President of Technical Operations with a deep background and expertise in process development and manufacturing of cell therapies Mr. Lucio Tozzi joined in January of 2024 as Senior Vice President of Global Clinical Operations having over 30 years of experience in clinical trial execution WINSTON-SALEM, N.C., March 25, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutic
